Vitrian

About Vitrian

Vitrian operates as a specialized, fully integrated provider focused on the biomanufacturing and cGMP (current Good Manufacturing Practice) facilities sector. The company was formally launched in the summer of 2022 by life sciences real estate veterans Scott Nudelman and Sam Johnson. Headquartered in Bethesda, Maryland, with offices in New York and Dallas, the firm was established to address a critical market need for a single-source platform to streamline the expansion of biomanufacturing infrastructure.

The founders, Nudelman and Johnson, identified the industry's pain point through their separate experiences in life sciences real estate, where clients repeatedly expressed frustration over the fragmented process of developing cGMP capacity. Scott Nudelman brings over 25 years of real estate investment experience, with a focus on strategic partnerships and workforce development initiatives. Sam Johnson has more than a decade of experience in real estate and investment, specializing in the development and financing of cGMP facilities across the United States. Their combined expertise formed the foundation of Vitrian's model, which inverts the traditional top-down real estate approach to a bottom-up, solutions-oriented one.

Vitrian's business model offers an end-to-end solution for life sciences companies, particularly those with positive Phase II or later clinical data readouts, and Contract Development and Manufacturing Organizations (CDMOs). The company generates revenue by providing a suite of services that cover the entire facility lifecycle. This includes creative capital solutions such as sale-leasebacks, equipment financing, and investments in development projects. The firm also delivers comprehensive facility development services, from market diligence and site selection to construction and facility design. Furthermore, Vitrian offers strategic advisory, including M&A due diligence and support, and fee-based project management services. A distinct aspect of its model is a commitment to civic engagement, focusing on workforce development by partnering with community colleges and non-profits to create training centers for the biomanufacturing workforce.

The company's core offering is a consolidated platform that integrates facility procurement, investment capital, and strategic services, thereby creating time and cost efficiencies for its clients. This integrated approach helps de-risk the complex process of building or acquiring manufacturing capacity. Vitrian has formed strategic partnerships, notably with cGMPnow, to provide a full design-build service that includes process equipment and validated manufacturing space. The company is active in multiple U.S. markets, with engagements spanning advanced therapeutics, synthetic biology, and radiopharma. A significant milestone was a $50 million investment into AmplifyBio's Manufacturing Enablement Center in Ohio, signaling its commitment to developing biomanufacturing hubs outside traditional clusters.